Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Change in Inventory (2025)

BridgeBio Pharma (BBIO) has disclosed Change in Inventory for 1 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Change in Inventory changed N/A to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at $25.3 million for FY2025, N/A changed from the prior year.
  • Change in Inventory hit $2.0 million in Q4 2025 for BridgeBio Pharma, down from $6.8 million in the prior quarter.
  • In the past five years, Change in Inventory ranged from a high of $13.4 million in Q2 2025 to a low of $2.0 million in Q4 2025.